Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine. (Q30360999)

20 June 2017

title

Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine. (English)

1 reference

20 June 2017

0 references

9

George F Gao

1 reference

20 June 2017

Ying Ju

1

1 reference

20 June 2017

Hongxia Fan

2

1 reference

20 June 2017

Jun Liu

3

1 reference

20 June 2017

Jun Hu

4

1 reference

20 June 2017

Xinghui Li

5

1 reference

20 June 2017

Changfei Li

6

1 reference

20 June 2017

Lizhao Chen

7

1 reference

20 June 2017

Qiang Gao

8

1 reference

20 June 2017

Songdong Meng

10

1 reference

20 June 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

20 June 2017

1 reference

20 June 2017

volume

32

1 reference

20 June 2017

issue

23

1 reference

20 June 2017

page(s)

2703-2711

1 reference

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Mechanism of action of clinically approved adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

The mechanism of action of MF59 - an innately attractive adjuvant formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

The importance of adjuvant formulation in the development of a tuberculosis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Vaccine Adjuvants: Putting Innate Immunity to Work

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

A universal epitope-based influenza vaccine and its efficacy against H5N1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Essential role of CD91 in re-presentation of gp96-chaperoned peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Phylogenetic Conservation of Glycoprotein 96 Ability to Interact with CD91 and Facilitate Antigen Cross-Presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Heat shock protein 70 inhibits the activity of Influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Treg suppress CTL responses upon immunization with HSP gp96.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Cross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive Individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Placenta-derived gp96 as a multivalent prophylactic cancer vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.045

10.1016/J.VACCINE.2014.03.045

7 January 2021

Identifiers

DOI

1 reference

20 June 2017

1 reference